Stategics, Inc.

Cytovia, Inc.

Axys Pharmaceuticals, Inc.

Jeffrey R Spencer

Juha Punnonen

Timothy J Church

Joane Litvak

James L Miller

Connie S Tettenborn

Karen Lariosa-Willingham

Sui Xiong Cai

Martin Sheringham Linsell

Thomas E Jenkins

Martin Sendzik

John A Drewe

Kenneth D Rice

Anthony R Gangloff

Emma Jane Shelton

David Sperandio

Neil Scott Cutshall

Vivian R Wang

Dimitri Leonoudakis

Dmitri Leonoudakis

Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies. 

Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival

Substituted triazolo-pyrimidine compounds for modulating cell proliferation  differentiation and survival

The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.

Thrombopoietin mimetics

The present invention is directed to substituted 1,4-thiazepine and analogs thereof, represented by the general Formula I:wherein the dashed lines, A, A, A, Xand Rare defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of capases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof

Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.

Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders

Growing community of inventors

South San Francisco, CA, United States of America

Jeffrey R Spencer